IsoRay wraps up feasibility study

Medical isotope developer IsoRay Medical of Richland, WA, has finished an initial feasibility study for the use of its cesium-131 brachytherapy seeds in accelerated partial-breast irradiation (APBI) procedures.

The firm said it conducted internal studies that used Monte Carlo simulations, image-based brachytherapy treatment planning, and physical dose measurements obtained from a phantom to evaluate cesium-131 internal radiation therapy in APBI treatment.

The initial studies prove cesium-131 internal radiation therapy to be a viable alternative to high-dose-rate radiation, according to IsoRay.

Related Reading

IsoRay reports NSCLC multicenter study, October 13, 2010

IsoRay revenue dips in FY10, September 28, 2010

IsoRay to distribute Hologic's GliaSite, June 23, 2010

IsoRay sales slip, net loss narrows, May 12, 2010

IsoRay sales grow in Q2, February 17, 2010

Copyright © 2010 AuntMinnie.com

Page 1 of 461
Next Page